|
|
Exchange: |
Nasdaq Small Cap |
Security
Type: |
Common |
Shares
Out: |
52,373,000 |
Market
Cap: |
2.32(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$30.85 - $52.9 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Health Services |
Level
III Sector: |
Medical Laboratories & Research |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 474 |
Guru Rank Value : 3 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile Vericel is a biopharmaceutical company providing cell therapies for the sports medicine and severe burn care markets. Co.'s products include: MACI®, which is an autologous cellularized scaffold product indicated for the repair of symptomatic, full-thickness cartilage defects of the knee with or without bone involvement in adults; and Epicel®, which is a permanent skin replacement for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns comprising greater than or equal to 30% of total body surface area. Co. also holds a license for North American rights to NexoBrid®, a registration-stage biological orphan product for debridement of severe thermal burns.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
126,152 |
256,428 |
308,234 |
348,833 |
Total Sell Value |
$5,873,218 |
$11,298,513 |
$13,114,420 |
$14,216,679 |
Total People Sold |
4 |
7 |
7 |
7 |
Total Sell Transactions |
9 |
26 |
34 |
37 |
End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Halpin Michael |
Chief Operating Officer |
|
2023-02-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,825 |
18,589 |
|
- |
|
Hopper Jonathan Mark |
Chief Medical Officer |
|
2023-02-19 |
4 |
D |
$29.82 |
$22,425 |
D/D |
(752) |
52,412 |
|
- |
|
Hopper Jonathan Mark |
Chief Medical Officer |
|
2023-02-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,750 |
53,164 |
|
- |
|
Flynn Sean C. |
SVP, General Counsel |
|
2023-02-19 |
4 |
D |
$29.82 |
$24,810 |
D/D |
(832) |
6,176 |
|
- |
|
Flynn Sean C. |
SVP, General Counsel |
|
2023-02-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,750 |
7,008 |
|
- |
|
Colangelo Dominick |
President and CEO |
|
2023-02-19 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,938 |
179,951 |
|
- |
|
Colangelo Dominick |
President and CEO |
|
2023-02-19 |
4 |
D |
$29.82 |
$123,544 |
D/D |
(4,143) |
175,808 |
|
- |
|
Siegal Jonathan |
Principal Accounting Officer |
|
2023-02-18 |
4 |
D |
$29.82 |
$4,831 |
D/D |
(162) |
932 |
|
- |
|
Siegal Jonathan |
Principal Accounting Officer |
|
2023-02-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
419 |
1,094 |
|
- |
|
Halpin Michael |
Chief Operating Officer |
|
2023-02-18 |
4 |
D |
$29.82 |
$39,720 |
D/D |
(1,332) |
14,764 |
|
- |
|
Halpin Michael |
Chief Operating Officer |
|
2023-02-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,813 |
16,096 |
|
- |
|
Hopper Jonathan Mark |
Chief Medical Officer |
|
2023-02-18 |
4 |
D |
$29.82 |
$33,041 |
D/D |
(1,108) |
51,414 |
|
- |
|
Hopper Jonathan Mark |
Chief Medical Officer |
|
2023-02-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,325 |
52,522 |
|
- |
|
Flynn Sean C. |
SVP, General Counsel |
|
2023-02-18 |
4 |
D |
$29.82 |
$34,442 |
D/D |
(1,155) |
5,258 |
|
- |
|
Flynn Sean C. |
SVP, General Counsel |
|
2023-02-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,325 |
6,413 |
|
- |
|
Mara Joseph Anthony Jr |
Chief Financial Officer |
|
2023-02-18 |
4 |
D |
$29.82 |
$31,758 |
D/D |
(1,065) |
13,697 |
|
- |
|
Mara Joseph Anthony Jr |
Chief Financial Officer |
|
2023-02-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,754 |
14,762 |
|
- |
|
Colangelo Dominick |
President and CEO |
|
2023-02-18 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,700 |
176,436 |
|
- |
|
Colangelo Dominick |
President and CEO |
|
2023-02-18 |
4 |
D |
$29.82 |
$161,714 |
D/D |
(5,423) |
171,013 |
|
- |
|
Halpin Michael |
Chief Operating Officer |
|
2023-02-11 |
4 |
D |
$29.30 |
$58,102 |
D/D |
(1,983) |
13,283 |
|
- |
|
Halpin Michael |
Chief Operating Officer |
|
2023-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,500 |
15,266 |
|
- |
|
Colangelo Dominick |
President and CEO |
|
2023-02-11 |
4 |
D |
$29.30 |
$102,990 |
D/D |
(3,515) |
164,736 |
|
- |
|
Colangelo Dominick |
President and CEO |
|
2023-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,500 |
168,251 |
|
- |
|
Hopper Jonathan Mark |
Chief Medical Officer |
|
2023-02-11 |
4 |
D |
$29.30 |
$24,612 |
D/D |
(840) |
50,197 |
|
- |
|
Hopper Jonathan Mark |
Chief Medical Officer |
|
2023-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,625 |
51,037 |
|
- |
|
402 Records found
|
|
Page 5 of 17 |
|
|